The Week in Review: July 14 – July 21, 2017

Friday, July 21, 2017 News Recap 1) Vosevi Approved in US – Under Review in Canada Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....

High Risk of Complications Post–Hep C Cure for Those With Advanced Liver Damage

The complications include liver cancer, failure, transplantation or death. Consistent medical monitoring is recommended. Individuals who are treated for hepatitis C virus (HCV) when they have advanced fibrosis or cirrhosis remain at high risk of liver disease progression even after being cured of the virus. Consequently, researchers recommend routine monitoring for this group. Publishing their findings in the Journal of Hepatology, researchers conducte

Brenda’s Story

MY JOURNEY – 2015, by Brenda Thorne Dedicated To: My grandchildren, whose mere presence on this earth gave me the courage to work hard to regain my strength and health. If I hadn’t wanted to watch them grow up, I might have given up. I wanted so badly to see each and every one of them. With 3 of them living in Texas, our Kitchener grandchild became the one who had all the responsibility of keeping Nana working hard. Her visits were so very importan

EMA to Review New Hep C Drugs for Possible Hep B Reactivation

The European Medicines Agency (EMA) has launched a review of the six direct-acting antivirals approved for use in the European Union for treating chronic hepatitis C virus infection, the agency said today.They are daclatasvir (Daklinza, Bristol-Myers Squibb), dasabuvir (Exviera, AbbVie), the combination of sofosbuvir and ledipasvir (Harvoni, Gilead Sciences), simeprevir (Olysio, Janssen), sofosbuvir (Sovaldi, Gilead Sciences), and the ombitasvir/paritaprev